NGNE Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
32.4M
-11.7%
36.7M
+10.0%
33.3M
+21.1%
27.5M
+15.7%
23.8M
R&D
23.5M
-7.6%
25.5M
+1.3%
25.1M
+21.9%
20.6M
+19.7%
17.2M
SG&A
8.9M
-21.0%
11.2M
+36.6%
8.2M
+19.0%
6.9M
+5.1%
6.6M
Operating Income
-32376000
+11.7%
-36670000
-10.0%
-33349000
-21.1%
-27529000
-15.7%
-23798000
EBITDA
-31555000
+12.0%
-35857000
-10.3%
-32502000
-21.5%
-26753000
-16.1%
-23034000
Net Income
-29023000
+15.8%
-34488000
-11.5%
-30934000
-25.1%
-24735000
-18.0%
-20953000
EPS (Basic)
$-1.05
+31.4%
$-1.53
-10.1%
$-1.39
-24.1%
$-1.12
-13.1%
$-0.99
EPS (Diluted)
$-1.05
+31.4%
$-1.53
-10.1%
$-1.39
-24.1%
$-1.12
-13.1%
$-0.99
Shares (Diluted)
27.7M
+22.8%
22.6M
+1.1%
22.3M
+1.0%
22.1M
+4.3%
21.2M
Neurogene (NGNE) — Financials